Altogether, these results support the notion that Alb-Flt3L, likely through its tissue accumulation and long half-life, can accumulate in the tumor-draining LNs and tumor, where it can expand cross-presenting DCs and allow for substantially improved priming and activation of T cells, ultimately leading to tumor control and long-term survival. This evidence concerns the gene FLT3LG and neoplasm.